Oslo, December 12, 2024 - Observe Medical ("the Company" or "Observe Medical")
announces that the order intake of UnoMeterT SafetiT Plus has now reached 18
countries and brings the current order intake beyond NOK 5 million only 4 weeks
after the product was launched.  The Company expects that this number will
continue to increase in the coming weeks. First deliveries are expected before
Christmas and will pick up speed in January and onwards.

Jørgen Mann, CEO of Observe Medical, commented, "We are seeing a continued
positive development in the order intake on our UnoMeterT portfolio, and
particularly on UnoMeterT SafetiT Plus. With the first deliveries starting
shortly we expect that we can continue taking back the historic market share of
the UnoMeterT family and thereby securing a strong distribution platform and
financial resources to support our ambition to become market leader within urine
output measurement".

For further information, please contact:

Jørgen Mann, CEO Observe Medical
Mobile: +45 408 67 558
E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe Medical
Mobile: +47 958 12 765
E-mail: johan.fagerli@observemedical.com

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in urine measurement and ultrasound, in combination with targeted M&A and
distribution. Observe Medical is working with a network of leading distributors
to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available at www.observemedical.com.